


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 28 MARCH 2025

Reference is made to the circular (the “**Circular**”) of Innovative Pharmaceutical Biotech Limited (the “**Company**”) and the Notice of the Special General Meeting dated 12 March 2025 (the “**Notice**”) and the announcements in relation to the proposed appointment of auditor dated 7 March 2025 and the closure of the register of members dated 13 March 2025. Unless the context otherwise requires, terms defined in this announcement shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE ANNUAL GENERAL MEETING

The Board is pleased to announce that at the Special General Meeting held on 28 March 2025, the proposed resolution as set out in the Notice was duly passed by the Shareholders by way of poll pursuant to Rule 13.39(4) of the Listing Rules.

Tricor Tengis Limited, the Company's branch share registrar, acted as the scrutineer for the purpose of the counting of votes at the Special General Meeting. The poll results of the resolution at the Special General Meeting is as follows:

ORDINARY RESOLUTION		For		Against	
		Number of Shares	%	Number of Shares	%
1.	To appoint SFAI (HK) CPA Limited as the auditor of the Company with effect from the date on which this resolution is adopted until the conclusion of the next general meeting of the Company and to authorise the board of directors of the Company to fix its remuneration.	682,772,490	100	0	0

As more than 50% of the votes were cast in favour of the above ordinary resolution, such resolution was duly passed by Shareholders by way of poll at the Special General Meeting.

As at the date of the Special General Meeting, a total of 1,822,202,924 Shares were in issue, which is the total number of Shares held by Shareholders entitled to attend and vote on the proposed resolution at the Special General Meeting. No Shareholder was required under the Listing Rules to abstain from voting at the Special General Meeting on the resolution proposed thereat. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolution proposed at the Special General Meeting as set out in Rule 13.40 of the Listing Rules.

The directors of the Company, Dr. Yeung Yung, Mr. Gao Yuan Xing, Mr. Tang Rong and Mr. Wang Rongliang, attended the Special General Meeting either in person or by electronic means.

By Order of the Board
Innovative Pharmaceutical Biotech Limited
Yeung Yung
Chairman

Hong Kong, 28 March 2025

As at the date of this announcement, the Board comprises Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Mr. Li Jiehong (executive Director), Ms. Qi Shujuan (executive Director), Ms. Jiang Nian (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director) and Mr. Chen Jinzhong (independent non-executive Director).

Please also refer to the published version of this announcement on the Company's website: www.ipb.asia and www.irasia.com/listco/hk/ipb.